Technological Advancements in the Analysis of Glycans Presents Business Opportunities
The global market for glycobiology was valued at $2.8 billion in 2021. The market is expected to grow at a compound annual growth rate (CAGR) of 11.1% to reach over $5.3 billion by the end of 2027. Market growth is attributed to factors such as technological advancements in the analysis of glycans, rising prevalence of chronic disorders globally, and increasing R&D investment by pharma companies. The global market for glycobiology is categorized into segments and regions.
Glycobiology is defined as the branch of biology concerned with the study of the structure, biosynthesis, and function of saccharides (sugar chains), which may exist purely or conjugated to other biological molecules to form glycoconjugates. Importantly, the study of such molecules is technically challenging as no sequencing tool, such as that used in proteomics or genomics, is available. However, following on from genomics and proteomics, there is increasing recognition of the importance of carbohydrate-based molecules in basic cellular processes. This has resulted in more extensive glycomics research focused on the glycosylation of therapeutic proteins, glycosylation patterns in cell recognition, cellular glyco profiling studies in cancer and other diseases, and improved chemical analysis and synthesis of carbohydrate molecules.
Glycobiology offers huge untapped potential for the discovery of new therapeutics originated from saccharides or other molecules that target the biosynthesis and function of saccharides. Saccharides offer a range of potential chemical varieties that is orders of magnitude greater than what their protein and nucleic acid counterparts can provide. In addition, saccharides have multiple functions that make them relevant to most areas of biological research. The central role of saccharides in cellular interactions means that novel oligosaccharides are of value in R&D programs addressing a wide range of therapeutic areas, including inflammation, immunity, oncology, neurodegenerative disease, infection,
and others.
However, the market for carbohydrate-based drugs is still in a relatively early stage of development. In addition to “monosaccharide-inspired”drugs such as Roche’s influenza treatment Tamiflu (oseltamivir), two blockbuster drugs, Bayer’s Glucobay (acarbose) and heparin, stand out. Heparin is a key example of a major carbohydrate-based molecule that has been developed for medical use in anticoagulant therapy.
Because of their essential function in many cellular processes, carbohydrates are also important biomarkers in diagnostic assay development. Several biotech companies are focusing on glycobiology approaches for further detection of various pathologies, including cancer and neurodegeneration. Major market players in glycobiology include ThermoFisher Scientific Inc., Agilent Technologies Inc., Bio-Techne, Merck KGaA, Takara Bio Inc., and Waters Corp. There are many other emerging and niche market players establishing their position in the market that stand out and that offer high-quality glycobiology products. All the market players are actively engaged in R&D of glycans to offer a strong product portfolio.
Report Scope
The current report will provide an in-depth look at the glycobiology market. This report analyzes glycobiology market trends with data from 2021, estimates for 2022, projections of compound annual growth rates through 2027 (forecast period of 2022 to 2027), and regional market data. This report will highlight the current and future market potential of glycobiology along with providing a detailed analysis of the competitive environment. Regulatory scenarios, drivers, restraints, and opportunities will be covered in the current report. The report also covers market projections for 2027 and indicates the market share for key market players.
The scope of the market in this report is segmented into the glycobiology segment and region. The segments of glycobiology are: glycobiology therapeutics, glycobiology diagnostics, and glycobiology reagents and tools. The regional markets are North America, Europe, Asia-Pacific, and other world regions (Rest of the World). Detailed analysis of major countries such as the U.S., Germany, the U.K., Italy, France, Japan, China, and India will be covered within their respective regional segments. For market estimates, data will be provided for 2021 as the base year, with forecasts for 2022 and 2027.
The report includes:
- 51 tables
- An up-to-date overview and analysis of the global markets for glycobiology diagnostics and therapeutics
- Analyses of the global market trends, with historic revenue data from 2019 to 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
- Highlights of the market potential for glycobiology market, industry growth drivers, and areas of focus to forecast this market into various segments and subsegments
- Estimation of the actual market size and revenue forecast for global glycobiology market in USD million terms, and corresponding market share analysis by major market segments and region
- A look at new tools for synthesizing, modifying and studying oligosaccharides and glycoconjugates
- Evaluation of promising candidates for carbohydrate-based diagnostics, drugs and vaccines
- Insight into how glycobiology offers enormous untapped potential in the discovery of new therapeutics derived from saccharides or other molecules which target the biosynthesis and function of saccharides
- Identification of leading biotechnology companies poised to introduce products during the forecast period, and their impact on the face of the competitive environment
- Insight into recent industry structure for glycobiology diagnostics and therapeutics, current competitive scenario, clinical trials, ongoing research (R&D) activities, strategic alliances, and COVID-19 impact on the progress of this market
- Profile descriptions of the major market players, including Agilent Technologies Inc., Bio-Techne, Merck KGaA, Takara Bio Inc. and Waters Corp.
Table of Contents
Chapter 1 Introduction1.1 Overview
1.2 Study Goals and Objectives
1.3 Reasons for Doing This Study
1.4 What's New in This Update?
1.5 Scope of Report
1.6 Information Sources
1.7 Methodology
1.8 Geographic Breakdown
1.9 Analyst's Credentials
1.10 Custom Research
1.11 Related Reports
Chapter 2 Summary and Highlights
Chapter 3 Market Dynamics
3.1 Market Drivers
3.1.1 Technological Advancements in the Analysis of Glycans
3.1.2 Rising Prevalence of Chronic Disorders Globally
3.1.3 Increasing R&D Investment by Pharma Companies
3.2 Market Restraints
3.2.1 Challenges in Glycobiology
3.3 Market Opportunities
3.3.1 Inorganic Strategies among Market Players
Chapter 4 Market Overview
4.1 Overview
4.1.1 Glycobiology
4.1.2 Significance of Glycan
4.1.3 Function of Glycans and Their Biological Significance
4.1.4 Structural Role of Glycans
4.1.5 Research Tools for Glycobiology Studies
4.1.6 Structural Analysis of Glycans
4.1.7 Glycomics as Part of Glycobiology Research
4.1.8 Chemical and Enzymatic Synthesis of Glycans and Glycoconjugates
4.1.9 Bioinformatics and Database Resources for Glycobiology Research
4.2 Current Market Trends
4.2.1 Protein and Glycan Glycoengineering
4.2.2 Engineering Glycans and Glycan Mimics as Therapeutic Agents
4.2.3 Glycobiology and Drug Delivery
4.2.4 Oligosaccharide Libraries for Drug Discovery Research
4.2.5 Glyconutrients as Therapeutics
4.3 Recent Strategic Alliances
4.4 Emerging Technologies
4.4.1 Glycans in Medicine and Biotechnology
4.4.2 Glycans in Nanotechnology, Bioenergy, and Materials Science
Chapter 5 Impact of COVID-19 on Market
5.1 Overview
5.2 COVID-19 Crisis
5.2.1 Impact on Market for Glycobiology
5.2.2 COVID-19 Measures
Chapter 6 Glycobiology Therapeutics Market
6.1 Overview
6.1.1 Subcategories of Glycobiology Therapeutics
6.1.2 Therapeutic Glycoproteins
6.1.3 Glycan Therapeutic Approaches to Metabolic Diseases
6.1.4 Therapeutic Applications of Glycosaminoglycans
6.1.5 Carbohydrate-based Vaccines and Glycans as Vaccine Components
6.1.6 Blocking Glycan Recognition in Diseases
6.1.7 Transfusion and Transplantation Rejection by Anti-glycan Antibodies
Chapter 7 Glycobiology Diagnostics Market
7.1 Overview
7.1.1 Glycobiomarkers and Autoimmunity
7.1.2 Glycobiomarkers in Inflammatory Bowel Disease
7.1.3 Autoantibodies Against Neuronal Glycans in Certain Neuropathies
7.1.4 Glycobiology Markers in Cardiovascular Diseases
7.1.5 Role of Glycans in the Histopathology of Alzheimer's Disease
7.1.6 Glycobiomarkers and Asthma
7.1.7 Glycobiomarkers in Infectious Disease Testing
7.1.8 Market Potential for Glycobiology-based Biomarkers and Diagnostic Tests
7.1.9 Glycobiology-based Cancer Biomarkers and Diagnostic Development
7.1.10 Carbohydrates as Potential Serum Biomarkers
7.1.11 Current Glycobiology-based Diagnostics on the Market
7.1.12 Companies with Glycobiology Diagnostic Platforms and Products in Development
7.1.13 Market for Glycobiology-based Diagnostics
Chapter 8 Glycobiology Reagents and Tools Market
8.1 Overview
8.1.1 Analytical and Chromatography Techniques
8.1.2 Glycan Arrays
8.1.3 Lectin Arrays
8.1.4 Glycobiology Kits
8.1.5 Reagents for Glycobiology Research
8.1.6 Carbohydrates: Monosaccharides, Oligosaccharides and Other Reagents
Chapter 9 Market Breakdown by Region
9.1 Overview
9.1.1 North America
9.1.2 Europe
9.1.3 Asia-Pacific
9.1.4 Rest of the World
Chapter 10 Analysis of Market Opportunities
10.1 Porter's Five Forces Analysis
10.1.1 Threat of New Entrants
10.1.2 Threat of Substitutes
10.1.3 Bargaining Power of Suppliers
10.1.4 Bargaining Power of Buyers
10.1.5 Degree of Competition
Chapter 11 Competitive Landscape
Chapter 12 Company Profiles
12.1 Major Companies
- Agilent Technologies
- AMSBio LLC
- Bio-Techne
- Isosep
- Ludger Ltd.
- Merck KGaA
- New England Biolabs
- Takara Bio Inc.
- Thermo Fisher Scientific Inc.
- Waters Corp.
List of Tables
Summary Table: Global Market for Glycobiology, by Segment, Through 2027
Table 1: Global Diabetes Prevalence, Estimates and Projections, 2019-2045
Table 2: Cases of Diabetes Worldwide, by Type, 2019
Table 3: Global Prevalence of Diabetes, by Type, Through 2040
Table 4: Global HIV Epidemic, by Age Group, 2020
Table 5: Market Players: R&D Investment, 2019-2021
Table 6: Classification of Carbohydrates
Table 7: Examples of Glycosylation Deficiency and Their Pathological Effect
Table 8: Experimental Approaches to Studying Glycans
Table 9: Examples of Inhibitors/Modulators Used in Glycobiology Research
Table 10: Separation and Identification Techniques Used for Glycan Analysis
Table 11: Bioinformatics and Database Resources for Glycobiology Research
Table 12: Strategic Alliances in the Market for Glycobiology, 2020-2022
Table 13: Approved Glycobiology-related Treatments and Carbohydrate-based Drugs
Table 14: Global Market for Glycobiology Therapeutics, by Region, Through 2027
Table 15: Glycobiology-based Markers
Table 16: Global Death Share, by Various Cancer Types, 2015
Table 17: FDA-approved Cancer Biomarkers Currently Used in Clinical Practice
Table 18: Examples of Potential Glycoprotein Cancer Biomarkers
Table 19: Companies with Diagnostic Products in Development Based on Glycobiology Research
Table 20: Global Market for Glycobiology Diagnostics, by Region, Through 2027
Table 21: Companies Offering Glycobiology Reagents
Table 22: Global Market for Glycobiology Reagents and Tools, by Region, Through 2027
Table 23: Global Market for Glycobiology, by Region, Through 2027
Table 24: Diabetes Estimates in North America, by Country, 2000-2045
Table 25: Influenza Disease Burden, by Age Group, U.S., 2019 and 2020 Influenza Season
Table 26: North American Market for Glycobiology, by Country, Through 2027
Table 27: Diabetes Estimates in Europe, by Country, 2000-2045
Table 28: European Market for Glycobiology, by Country, Through 2027
Table 29: Tuberculosis Burden of Asian Countries, by Country, 2019
Table 30: Diabetes Estimates for the Asia-Pacific Region, by Country, 2000-2045
Table 31: Asia-Pacific Market for Glycobiology, by Country, Through 2027
Table 32: Diabetes Estimates in RoW, by Country, 2000-2045
Table 33: New Cancer Cases in Africa, by Cancer Type, 2020 and 2024
Table 34: Porter’s Five Forces Analysis: Glycobiology Market
Table 35: Agilent Technologies: Product Portfolio
Table 36: Agilent Technologies: Key Developments, 2016-2020
Table 37: AMSBIO LLC: Product Portfolio
Table 38: AMSBIO LLC: Key Developments, 2022
Table 39: Bio-Techne: Product Portfolio
Table 40: IsoSep: Product Portfolio
Table 41: Ludger Ltd.: Product Portfolio
Table 42: Ludger Ltd.: Key Developments, 2022
Table 43: Merck KGaA: Product Portfolio
Table 44: Merck KgaA: Key Developments, 2020 and 2021
Table 45: New England Biolabs: Insulin Product Portfolio
Table 46: Takara Bio Inc.: Product Portfolio
Table 47: Thermo Fisher Scientific Inc.: Product Portfolio
Table 48: Thermo Fisher Scientific Inc.: Key Developments, 2020
Table 49: Waters Corp.: Product Portfolio
Table 50: Acronyms Used in This Report
List of Figures
Summary Figure: Global Market Shares of Glycobiology, by Segment, 2021
Figure 1: Emerging Glycomics Technologies
Figure 2: Cases of Diabetes Worldwide, by Type, 2019
Figure 3: Global Prevalence of Diabetes, by Type, 2018-2040
Figure 4: Numbers and Shares of New Cancer Cases, Women, 2020
Figure 5: Numbers and Shares of New Cancer Cases, Men, 2020
Figure 6: Schematic Presentation of O- and N-linked Glycans on Protein Receptor
Figure 7: Global Market for Glycobiology Therapeutics, 2019-2027
Figure 8: Global Market for Glycobiology Diagnostics, 2019-2027
Figure 9: Global Market for Glycobiology Reagents and Tools, 2019-2027
Figure 10: Global Market Shares of Glycobiology, by Region, 2021
Figure 11: North American Market Shares of Glycobiology, by Country, 2021
Figure 12: Cancer Diagnosis Share in Europe, by Gender, 2020
Figure 13: European Market Shares of Glycobiology, by Country, 2021
Figure 14: Asia-Pacific Market Shares of Glycobiology, by Country, 2021
Figure 15: Global Market Shares of Glycobiology, by Company, 2021
Figure 16: Agilent Technologies: Annual Revenue, 2019-2021
Figure 17: Agilent Technologies: Revenue Share, by Segment, 2021
Figure 18: Agilent Technologies: Revenue Share, by Region, 2021
Figure 19: Bio-Techne: Annual Revenue, 2019-2021
Figure 20: Bio-Techne: Revenue Share, by Business Segment, 2021
Figure 21: Bio-Techne: Revenue Share, by Region, 2021
Figure 22: Merck KGaA: Annual Revenue, 2019-2021
Figure 23: Merck KGaA: Revenue Share, by Business Segment, 2021
Figure 24: Merck KGaA: Revenue Share, by Region, 2021
Figure 25: Takara Bio Inc.: Annual Revenue, 2019-2021
Figure 26: Takara Bio Inc.: Revenue Share, by Segment, 2021
Figure 27: Takara Bio Inc.: Revenue Share, by Region, 2021
Figure 28: Thermo Fisher Scientific Inc.: Annual Revenue, 2019-2021
Figure 29: Thermo Fisher Scientific Inc.: Revenue Share, by Segment, 2021
Figure 30: Thermo Fisher Scientific Inc.: Revenue Share, by Region, 2021
Figure 31: Waters Corp.: Annual Revenue, 2019-2021
Figure 32: Waters Corp.: Revenue Share, by Segment, 2021
Figure 33: Waters Corp.: Revenue Share, by Region, 2021
Companies Mentioned
- Agilent Technologies
- AMSBio LLC
- Bio-Techne
- Isosep
- Ludger Ltd.
- Merck KGaA
- New England Biolabs
- Takara Bio Inc.
- Thermo Fisher Scientific Inc.
- Waters Corp.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 123 |
| Published | March 2023 |
| Forecast Period | 2022 - 2027 |
| Estimated Market Value ( USD | $ 3.2 Billion |
| Forecasted Market Value ( USD | $ 5.3 Billion |
| Compound Annual Growth Rate | 11.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
